Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7475 pages
Showing 3101 - 3150Pooled Analysis of Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy in NSCLC
In a study reported in JAMA Oncology, Kichenadasse et al found that high body mass index was associated with improved overall survival in patients with advanced non–small cell lung cancer (NSCLC) treated with atezolizumab. As noted by the investigators, there are data showing that high BMI is...
Are Patient-Reported Outcomes Predictive of Survival and Likelihood of Hospitalization?
In a study reported in JCO Oncology Practice, Kerrigan et al found that patient-reported outcomes (PROs), obtained by using the National Cancer Institute (NCI) Patient-Reported Outcomes Measurement Information System–Cancer (PROMIS-Ca) Bank, may be prognostic for outcomes in patients with advanced...
Activity of Anti-BCMA BiTE Molecule AMG 420 in Relapsed or Refractory Multiple Myeloma
In a phase I study reported in the Journal of Clinical Oncology, Max S. Topp, MD, and colleagues found the maximum tolerated dose of the investigational anti–B cell maturation antigen (BCMA) bispecific T-cell engager (BiTE) molecule AMG 420 elicited a high response rate in patients with relapsed or ...
Dual VEGF and PD-1 Inhibition in Advanced Solid Tumors
In a phase Ib/II trial reported in the Journal of Clinical Oncology, Taylor et al found the combination of the VEGF inhibitor lenvatinib and the programmed cell death protein 1 (PD-1) inhibitor pembrolizumab showed activity across a range of advanced solid tumors. As stated by the authors, there is ...
Cemiplimab in Locally Advanced Cutaneous Squamous Cell Carcinoma
As reported in The Lancet Oncology by Migden et al, a phase II trial has shown activity of cemiplimab in patients with locally advanced cutaneous squamous cell carcinoma. The trial supported the September 2018 U.S. Food and Drug Administration approval of cemiplimab in this setting. In this report, ...
Olaparib as Maintenance Therapy for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
On December 27, 2019, the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib was approved for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma, as detected by a U.S. Food and Drug Administration...
Olaparib for Previously Treated, Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations
In the phase II TOPARP-B trial—reported by Joaquin Mateo, MD, in The Lancet Oncology—investigators found that olaparib showed good activity in men with metastatic castration-resistant prostate cancer and DNA damage response (DDR) gene aberrations who had received one or two prior taxane regimens....
TIVO-3: Third- or Fourth-Line Tivozanib vs Sorafenib in Metastatic Renal Cell Carcinoma
As reported in The Lancet Oncology by Brian I. Rini, MD, and colleagues, the phase III TIVO-3 trial has shown a statistically significant increase in progression-free survival with tivozanib vs sorafenib as a third- or fourth-line treatment for advanced renal cell carcinoma. Study Details The...
First-Line Atezolizumab Plus Nab-paclitaxel in Advanced Triple-Negative Breast Cancer: Second Overall Survival Interim Analysis
As reported in The Lancet Oncology by Peter Schmid, MD, and colleagues, the prespecified second interim analysis of overall survival in the phase III IMpassion130 trial has shown no overall survival benefit with the addition of atezolizumab to nab-paclitaxel as first-line treatment of...
Recurrence Risk in Black and White Women With Borderline Estrogen Receptor–Positive Breast Cancer
In a study reported in the Journal of the National Cancer Institute, Halei C. Benefield, PhD, and colleagues found that black women with borderline estrogen receptor (ER)-positive breast cancer had significantly poorer disease-free interval compared with those with ER-positive disease, irrespective ...
Enfortumab Vedotin-ejfv for Previously Treated Advanced Urothelial Cancer
On December 18, 2019, the antibody-drug conjugate enfortumab vedotin-ejfv (PadcevTM) was granted accelerated approval for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed cell death protein 1 (PD-1) or programmed cell...
Fam-trastuzumab Deruxtecan-nxki for Previously Treated Unresectable or Metastatic HER2-Positive Breast Cancer
On December 20, 2019, the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki was granted accelerated approval in the treatment of patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti–HER2-based regimens in the metastatic setting.1,2...
Atezolizumab With Chemotherapy for Metastatic Nonsquamous NSCLC Without EGFR/ALK Aberrations
On December 3, 2019, atezolizumab in combination with nab-paclitaxel and carboplatin was approved for first-line treatment of metastatic nonsquamous non–small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumore aberrations.1,2 The approval was based on findings in the open-label phase III...
Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer
On December 16, 2019, enzalutamide (Xtandi) was approved for the treatment of patients with metastatic castration-sensitive prostate cancer.1,2 Supporting Efficacy Data The current approval was based on findings from the phase III double-blind ARCHES trial (ClinicalTrials.gov identifier...
Pathologic Fracture and Prognosis in Adult and Pediatric Patients With High-Grade Osteosarcoma
In a study reported in the Journal of Clinical Oncology, Kelley et al found that pathologic fracture was associated with poorer overall survival among adult—but not pediatric—patients with primary central high-grade osteosarcoma of the extremities. Study Details The study involved retrospective...
Price Transparency and Variation for Prostate Cancer Radiation Therapy
In a study reported in JAMA Oncology, Trevor Royce, MS, MD, MPH, and colleagues found that publicly available information on pricing for radiation treatment for prostate cancer was complex and inconsistent, and that pricing varied widely among National Cancer Institute (NCI)-designated cancer...
Immune-Related Adverse Events and Recurrence-Free Survival With Adjuvant Immunotherapy vs Placebo in Stage III Melanoma
In an analysis of the EORTC 1325/KEYNOTE-054 trial of adjuvant pembrolizumab vs placebo in stage III melanoma reported in JAMA Oncology, Alexander M.M. Eggermont, MD, PhD, and colleagues found that patients treated with pembrolizumab who experienced immune-related adverse events had improved...
Impact of the NCI Cell-Line Database: A Testament to Patient Altruism
In an homage to the gracious patients who provided biospecimens and to the dedicated researchers who have tended and studied the derived cell lines, James L. Mulshine, MD, of the Center for Healthy Aging, Department of Internal Medicine, Rush University, and colleagues have described the impact of...
Relapse and Outcomes in Men Receiving Adjuvant Bleomycin/Etoposide/Cisplatin for Clinical Stage I Nonseminoma
In a study reported in the Journal of Clinical Oncology, Fischer et al found different patterns of relapse and associated outcomes among men with relapse after treatment with adjuvant bleomycin/etoposide/cisplatin for clinical stage I nonseminoma. The study included data on 51 patients from 18...
Entrectinib in Advanced ROS1 Fusion–Positive NSCLC
As reported in The Lancet Oncology by Alexander Drilon, MD, and colleagues, an integrated analysis of three phase I/II trials has shown high activity of the TRK and ROS1 inhibitor entrectinib in ROS1 fusion-positive non–small cell lung cancer (NSCLC). This analysis supported the August 2019 U.S....
External-Beam Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation After Breast-Conserving Surgery in DCIS or Node-Negative Breast Cancer
As reported in The Lancet by Timothy J. Whelan, BM, BCh, and colleagues, the phase III noninferiority RAPID trial has shown that external-beam accelerated partial-breast irradiation is noninferior to whole-breast irradiation in reducing risk of local recurrence after breast-conserving surgery in...
Conditioning Intensity for Allogeneic Transplantation in Patients With AML
In a study reported in the Journal of Clinical Oncology, Hourigan et al found that reduced-intensity conditioning for allogeneic hematopoietic cell transplantation was associated with poorer outcomes vs myeloablative conditioning in patients with acute myeloid leukemia (AML) who had genomic...
Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous NSCLC
In a Japanese phase III trial reported in the Journal of Clinical Oncology, Seto et al found that the addition of maintenance pemetrexed to bevacizumab did not significantly improve overall survival in patients with previously untreated, advanced nonsquamous non–small cell lung cancer (NSCLC)...
Different Doses of Adjuvant Ipilimumab vs High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
As reported in the Journal of Clinical Oncology by Tarhini et al, the phase III Intergroup E1609 trial has shown an overall survival advantage with adjuvant ipilimumab at 3 mg/kg—but not at 10 mg/kg—vs high-dose interferon alfa-2b in patients with resected high-risk cutaneous melanoma. The...
Are Racial/Ethnic Disparities in Breast Cancer Diagnosis Caused by Health Insurance Coverage?
Lack of insurance coverage is a major cause of delayed breast cancer screening and treatment among minority women, which could lead to a decrease in a patient’s chance of survival. Nearly half of the disparity in later-stage diagnosis between non-Hispanic white women and black, Hispanic, and...
Patient-Reported Functional Outcomes With Hypofractionated vs Conventionally Fractionated Radiotherapy for Nonmetastatic Prostate Cancer
In a national cohort study conducted in the United Kingdom and reported in the Journal of Clinical Oncology, Nossiter et al found no clinically important differences in patient-reported functional outcomes among men receiving hypofractionated vs conventionally fractionated radiotherapy for...
Activity of Belantamab Mafodotin in Patients With Heavily Pretreated Relapsed or Refractory Multiple Myeloma
In the phase II DREAMM-2 trial reported in The Lancet Oncology, Sagar Lonial, MD, and colleagues found that the antibody-drug conjugate belantamab mafodotin was active in patients with heavily pretreated relapsed or refractory multiple myeloma. The agent is a conjugate of an anti–B-cell maturation...
Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes
In the phase III MEDALIST trial reported in The New England Journal of Medicine, Fenaux et al found that luspatercept significantly reduced the severity of anemia vs placebo in red blood cell transfusion–dependent patients with very low- to intermediate-risk myelodysplastic syndromes with ring...
ADMIRAL Trial: Gilteritinib Improves Overall Survival in Relapsed or Refractory FLT3-Mutated AML
As reported in The New England Journal of Medicine by Alexander E. Perl, MD, of Abramson Cancer Center, University of Pennsylvania, and colleagues, the phase III ADMIRAL trial showed improved overall survival with the oral FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib vs salvage...
Entrectinib in Advanced or Metastatic NTRK Fusion–Positive Solid Tumors
As reported in The Lancet Oncology by George D. Demetri, MD, and colleagues, integrated analysis of three phase I/II trials has shown high levels of activity of the tropomyosin receptor kinase (TRK) inhibitor entrectinib in advanced NTRK fusion–positive solid tumors. This analysis supported the...
Activity of Ruxolitinib in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
In a phase II study reported in the Journal of Clinical Oncology, Dao et al found that the JAK1/2 inhibitor ruxolitinib was active in patients with chronic neutrophilic leukemia (CNL), with less activity observed in those with atypical chronic myeloid leukemia (CML) and greater activity observed...
Is There an Association Between Powder Use and Risk of Ovarian Cancer?
As reported in JAMA by O’Brien et al, pooled data from four large U.S.-based prospective cohorts suggest the lack of a significant association between the use of powder in the genital area and an increased risk of ovarian cancer. The investigators noted that the analysis may have not been...
Does Adding Trastuzumab to Adjuvant Chemotherapy Improve Invasive Disease–Free Survival for Patients With HER2-Negative Breast Cancer?
As reported in the Journal of Clinical Oncology by Louis Fehrenbacher, MD, and colleagues, the phase III NSABP B-47/NRG Oncology trial has shown no invasive disease–free survival benefit with the addition of trastuzumab to adjuvant chemotherapy therapy in patients with HER2-negative breast cancer...
Dietary Supplement Use During Adjuvant Chemotherapy and Treatment Outcomes in Patients With Early Breast Cancer
As reported in the Journal of Clinical Oncology by Ambrosone et al, an analysis of the SWOG S0221 trial population suggests that use of antioxidant and nonantioxidant dietary supplements, but not multivitamins, before and during adjuvant chemotherapy may be associated with poorer treatment outcomes ...
Addition of Olaparib to Bevacizumab Maintenance in Patients With Advanced Ovarian Cancer Responding to First-Line Therapy
As reported in The New England Journal of Medicine by Isabelle Ray-Coquard, MD, PhD, and colleagues, the phase III PAOLA-1 trial has shown a progression-free survival benefit with the addition of olaparib to bevacizumab maintenance in patients with advanced ovarian cancer responding to first-line...
Noninferiority of Four vs Six Cycles of CHOP for Patients With Favorable Prognosis B-Cell Lymphoma: FLYER Trial
As reported in The Lancet by Viola Poeschel, MD, and colleagues, the phase III FLYER trial has shown noninferiority of progression-free survival with four vs six cycles of cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) in combination with six doses of rituximab in patients with...
Recurrence Risk With Accelerated Partial- vs Whole-Breast Irradiation After Breast-Conserving Surgery for Early Breast Cancer: Long-Term Follow-up
As reported in The Lancet by Frank A. Vicini, MD, and colleagues, 10-year follow-up in the phase III NSABP B-39/RTOG 0413 equivalence trial has shown that accelerated partial-breast irradiation did not achieve equivalence to whole-breast irradiation in preventing local recurrence in women receiving ...
Olaparib for Previously Treated, Metastatic Castration-Resistant Prostate Cancer With DNA Repair Gene Aberrations
In the phase II TOPARP-B trial—reported by Mateo et al in The Lancet Oncology—investigators found that olaparib showed activity in men with metastatic castration-resistant prostate cancer and DNA damage response (DDR) gene aberrations who had received one or two prior taxane regimens. Study...
Is Pembrolizumab Active in Pediatric Patients With PD-L1–Positive Advanced Solid Tumors or Lymphoma?
Interim analysis of the phase I/II KEYNOTE-051 trial, reported in The Lancet Oncology by Geoerger et al, indicated minimal activity of pembrolizumab in pediatric patients with programmed cell death ligand 1 (PD-L1)-positive advanced, relapsed, or refractory solid tumors; however, activity was...
FDA Pooled Analysis of CDK4/6 Inhibitor Treatment for Advanced Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a U.S. Food and Drug Administration (FDA) pooled analysis reported in The Lancet Oncology, Jennifer J. Gao, MD, and colleagues found that the magnitude of progression-free survival benefit with the addition of a cyclin-dependent kinase (CDK) 4/6 inhibitor to endocrine therapy in women with...
Long-Term Results of Standard- vs High-Dose Chemoradiotherapy With or Without Cetuximab in Patients With Stage III NSCLC
As reported in the Journal of Clinical Oncology by Jeffrey D. Bradley, MD, and colleagues, long-term results of the phase III NRG Oncology/RTOG 0617 trial indicate that standard-dose radiotherapy should remain the standard of care in chemoradiotherapy for nonresectable stage III non–small cell...
Pembrolizumab in KRAS-Mutant and Wild-Type PD-L1–Positive Nonsquamous NSCLC
In an analysis reported in Annals of Oncology, Roy S. Herbst, MD, PhD, and colleagues found that pembrolizumab was active in both KRAS-mutant and wild-type tumors in a subgroup of patients in the KEYNOTE-042 trial with programmed cell death ligand 1 (PD-L1)-positive nonsquamous non–small cell lung...
Neoadjuvant vs Concurrent ADT With Dose-Escalated Radiotherapy for Localized Prostate Cancer
In a two-institute phase III trial reported in the Journal of Clinical Oncology, Malone et al found no difference in biochemical relapse–free survival with androgen-deprivation therapy (ADT) initiated prior to or concurrently with dose-escalated external-beam radiotherapy in patients with localized ...
Rates of Guideline-Aligned Genomic Profiling in Patients Diagnosed With Metastatic Colon Cancer
In a study reported in JCO Precision Oncology, Gutierrez et al found that most patients in a U.S. sample diagnosed with metastatic colon cancer between 2013 and 2017 did not receive guideline-aligned genomic testing for RAS, BRAF, and microsatellite instability/mismatch repair–deficiency (MSI/dMMR) ...
Overall Survival With the Addition of Ribociclib to Fulvestrant in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer: MONALEESA-3
As reported in The New England Journal of Medicine by Dennis J. Slamon, MD, PhD, and colleagues, in the phase III MONALEESA-3 trial, the second interim analysis of overall survival has shown a significant benefit with the addition of ribociclib to fulvestrant in first- or second-line treatment of...
Overall Survival With the Addition of Daratumumab to VMP in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
As reported in The Lancet by Maria-Victoria Mateos, MD, and colleagues, interim analysis of overall survival in the phase III ALCYONE trial has shown a significant benefit of the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in patients with newly diagnosed multiple...
Long-Term Results of IBIS-II: Anastrozole for Breast Cancer Prevention
As reported by Jack Cuzick, PhD, and colleagues in The Lancet, blinded follow-up of the IBIS-II trial has shown the continued benefit of anastrozole vs placebo in preventing breast cancer in high-risk postmenopausal women during the 5-year posttreatment period. For the international double-blind...
Cardiovascular Risks After Bleomycin/Etoposide/Cisplatin Treatment for Germ Cell Cancer
In a Danish study reported in the Journal of Clinical Oncology, Lauritsen et al found that patients treated for germ cell cancer exhibited an increase of cardiovascular risk factors and cardiovascular disease at short- and long-term follow-up. Study Details The study involved 5,185 patients with...
Osimertinib in Patients With NSCLC Harboring Uncommon EGFR Mutations
In a Korean phase II study reported in the Journal of Clinical Oncology, Myung-Ju Ahn, MD, PhD, and colleagues found that osimertinib was active in patients with metastatic or recurrent non–small cell lung cancer (NSCLC) with uncommon EGFR mutations. Study Details In the multicenter study, 36...
D-CARE Trial: Adjuvant Denosumab for Patients With Early Breast Cancer
As reported in The Lancet Oncology by Robert Coleman, MD, FRCP, and colleagues, the phase III D-CARE trial has shown no benefit of adjuvant therapy with the RANKL inhibitor denosumab vs placebo in improving bone metastasis–free survival in women with moderate- to high-risk early breast cancer....
